<DOC>
	<DOCNO>NCT00212797</DOCNO>
	<brief_summary>The primary purpose study determine whether subject psychotic major depression benefit adjunctive treatment Org 34517 . Two dos Org 34517 compare placebo international multicenter study . The duration trial 6 week .</brief_summary>
	<brief_title>A Study Determine Efficacy Safety 2 Doses Org 34517 Adjunctive Therapy Subjects With Psychotic Major Depression ( 28130 ) ( P05845 )</brief_title>
	<detailed_description>Major depression psychotic feature ( psychotic depression ) debilitate disorder depressive disorder spectrum . It associate severe symptom , prolonged course , poor response rate , residual symptom , frequent relapse high mortality , compare major depressive disorder . The markedly abnormal HPA axis function psychotic depression encourage research investigate whether HPA axis would target pharmacotherapy depression . The primary purpose study determine whether subject psychotic major depression benefit adjunctive treatment GR antagonist Org 34517 . Two dos Org 34517 compare placebo international multicenter study . The duration trial 6 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>provide voluntary write informed consent trial participation scope nature investigation explain , start trialrelated activity ( Screening ) ; able speak , read , understand , respond question , follow instruction English native language ; DSMIV severe depressive episode psychotic feature , diagnose MINI single recurrent episode ( 296.24 296.34 ) ; score PANSS item `` Delusions '' AND/OR `` Hallucinatory behavior '' least 4 Screening Baseline ; PANSS Positive Scale score least 16 Screening Baseline ; total score least 18 HAMD 17item scale Screening Baseline ; stable dose `` usual treatment '' , consist antidepressant , antipsychotic , mood stabilizer combination 3 drug class ; 18 75 year age ( inclusive ) Screening ; willing hospitalize least 11 day Screening onwards . current psychiatric diagnosis ( accord MINI ) except MDD , organic mental syndrome disorder , delirium anxiety disorder ; lifetime psychiatric diagnosis psychotic disorder ( accord MINI ) , MINI diagnosis past manic episode ; significant risk commit suicide , indicate score great 9 revise InterSePT Scale Suicidal Thinking ( ISST ) ; currently treat carbamazepine valproate ; currently treat midazolam ; treat electroconvulsive therapy current episode ; currently treat one antidepressant ; currently treat one antipsychotic ; currently treat one mood stabilizer ; `` usual treatment '' start discontinue 2 week Randomization ; `` usual treatment '' dose change within week prior Randomization ; clinically unstable uncontrollable renal , hepatic , respiratory , hematological , cardiovascular cerebrovascular disease would put patient risk safety bias assessment efficacy ; know hypersensitivity reaction glucocorticoid antagonist ; clinically significant abnormal laboratory data ( e.g . aspartate amino transferase ( ASAT ) and/or alanine amino transferase ( ALAT ) value &gt; 2x normal range upper limit ) ECG result , clinically significant abnormal outcome physical examination screen visit ; untreated uncompensated clinically significant endocrine disorder ; MINI diagnosis alcohol and/or drug dependence ; confirm positive result drug screen test illicit drug , except cannabis , Screening ; use hormone replacement therapy Screening ; require concomitant treatment corticosteroid , like dexamethasone , prednisone cortisol ( topical use allow ) ; diagnose Cushing 's disease ; woman childbearing potential without adequate contraception ; woman positive pregnancy test Screening Baseline , breastfeed mother ; male current diagnosis prostate hypertrophia past history ( le 3 month ) symptoms prostate hypertrophia . currently treat clozapine ( per Amendment III ) ; currently treat systemic topical ketaconazole .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>